Skip to search boxSkip to navigationSkip to main content

Adjusting MtDNA quantification in whole blood for peripheral blood platelet and leukocyte counts

  • ,
  • Marta Ledesma
    ,
  • Monica Gonzalez-Lazaro
    ,
  • Raquel Moreno-Loshuertos
    ,
  • Patricio Fernandez-Silva
    ,
  • Jose Antonio Enriquez
  • ,
  • Boca Raton Clinical Research Global Peru
    ,
  • Centro Nacional de Investigaciones Cardiovasculares Carlos III
    ,
  • Universidad Autónoma de Madrid
    ,
  • Instituto Aragonés de Ciencias de la Salud
    ,
  • Universidad de Zaragoza
Research Output:
Contribution to journal
Article
Peer-review

Open access

Publication Information

Output type

Research Output:
Contribution to journal
Article
Peer-review

Original language

English

Article number

e0163770

Journal (Volume, Issue Number)

PLoS ONE (Volume 11, Issue 10)

Publication milestones

  • Published - 10/2016

Publication status

Published - 10/2016

Publication IDs

  • Scopus: 84991694076
  • PubMed: 27736919

Abstract

Alterations of mitochondrial DNA copy number (mtDNAcn) in the blood (mitochondrial to nuclear DNA ratio) appear associated with several systemic diseases, including primary mitochondrial disorders, carcinogenesis, and hematologic diseases. Measuring mtDNAcn in DNA extracted from whole blood (WB) instead of from peripheral blood mononuclear cells or buffy coat may yield different results due to mitochondrial DNA present in platelets. The aim of this work is to quantify the contribution of platelets to mtDNAcn in whole blood [mtDNAcn(WB)] and to propose a correction formula to estimate leukocytes' mtDNAcn [mtDNAcn(L)] from mtDNAcn(WB). Blood samples from 10 healthy adults were combined with platelet-enriched plasma and saline solution to produce artificial blood preparations. Aliquots of each sample were combined with five different platelet concentrations. In 46 of these blood preparations, mtDNAcn was measured by qPCR. MtDNAcn(WB) increased 1.07 (95%CI 0.86, 1.29; p<0.001) per 1000 platelets present in the preparation. We proved that leukocyte count should also be taken into account as mtDNAcn(WB) was inversely associated with leukocyte count; it increased 1.10 (95%CI 0.95, 1.25, p<0.001) per unit increase of the ratio between platelet and leukocyte counts. If hematological measurements are available, subtracting 1.10 the platelets/leukocyte ratio from mtDNAcn(WB) may serve as an estimation for mtDNAcn(L). Both platelet and leukocyte counts in the sample are important sources of variation if comparing mtDNAcn among groups of patients when mtDNAcn is measured in DNA extracted from whole blood. Not taking the platelet/leukocyte ratio into account in whole blood measurements, may lead to overestimation and misclassification if interpreted as leukocytes' mtDNAcn.

Funding Details

The work of Dr. Laclaustra was supported in part by grants PI10/00021 and PI14/00009 from Instituto de Salud Carlos III, which include FEDER funding, providing funds for research material. Yamilee Hurtado-Roca was supported, in the form of salary, by FINCyT Science and Technology Program Scholarships N°088-FINCyT-BDE-2014 from agreement 1663/OC-PE, between the Republic of Peru and the Inter-American Development Bank. None of the funding institutions had any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
FundersFunding numbers
FINCyT Science and Technology Program
-
IDB
-
ISCIII
-
ERDF
-

Publication metrics

Metrics

Scopus
Citations

PlumX, opens in new tab

Mentions
1
Captures
68
Citations
66